Malwina Sołtysiak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Malwina Sołtysiak has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Agnieszka Tuzimek
Cardiovascular Clinic, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland
1 shared publication Izabela Orzołek
1 shared publication- Karolina Paralusz
Students’ Research Group “Alveolus”, Medical University of Warsaw, 02-091 Warsaw, Poland
1 shared publication Katarzyna Koziak
Department of Immunology, Biochemistry and Nutrition, Medical University of Warsaw, Warszawa, Poland
1 shared publicationMagdalena Paplińska-Goryca
Department of Internal Medicine, Pulmonary Diseases & Allergy, Medical University of Warsaw, Warszawa, Poland
1 shared publication- Magdalena Paplińska-Goryca
Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, 02-091 Warsaw, Poland
1 shared publication
Latest Publications
- Open Access
- 6 November 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1997512
Entrectinib-associated perimyocarditis in ROS1-positive NSCLC: a diagnostic and therapeutic dilemma — a case report
Background and clinical significance: Entrectinib is an effective therapy for ROS1-positive metastatic non-small cell lung cancer (NSCLC), but rare cardiotoxicity can easily be overlooked due to its non-specific presentation. Case presentation: We report the case of a 55-year-old woman with ROS1-positive NSCLC who developed persistent fever and hypotension (85/60 mmHg) after three months of entrectinib, despite achieving excellent tumour regression. Sepsis or neoplastic fever was initially suspected; however, she subsequently developed progressive dyspnoea and acute respiratory failure with rising cardiac biomarkers despite a preserved left ventricular ejection fraction (58%). Multiparametric cardiac magnetic resonance (CMR) findings were consistent with perimyocarditis, and endomyocardial biopsy was not performed. Following drug withdrawal and initiation of therapy for heart failure with preserved ejection fraction (HFpEF) along with colchicine and naproxen for pericardial inflammation, gradual cardiac recovery was achieved, but the tumour rapidly progressed within 13 days (from 22 to 35 mm). Entrectinib was reintroduced at a reduced dose (200 mg daily), yet recurrent cardiopulmonary failure occurred two weeks later, requiring permanent discontinuation. Conclusions: This case highlights that entrectinib-associated perimyocarditis can mimic infection, emphasizing the role of advanced non-invasive cardiac imaging, particularly CMR, in establishing the diagnosis. It underscores the profound therapeutic challenge of balancing the life-prolonging benefits of targeted oncological therapy against severe, recurrent cardiotoxicity.
- 6 November 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1997512
Open AccessEntrectinib-associated perimyocarditis in ROS1-positive NSCLC: a diagnostic and therapeutic dilemma — a case report
Background and clinical significance: Entrectinib is an effective therapy for ROS1-positive metastatic non-small cell lung cancer (NSCLC), but rare cardiotoxicity can easily be overlooked due to its non-specific presentation. Case presentation: We report the case of a 55-year-old woman with ROS1-positive NSCLC who developed persistent fever and hypotension (85/60 mmHg) after three months of entrectinib, despite achieving excellent tumour regression. Sepsis or neoplastic fever was initially suspected; however, she subsequently developed progressive dyspnoea and acute respiratory failure with rising cardiac biomarkers despite a preserved left ventricular ejection fraction (58%). Multiparametric cardiac magnetic resonance (CMR) findings were consistent with perimyocarditis, and endomyocardial biopsy was not performed. Following drug withdrawal and initiation of therapy for heart failure with preserved ejection fraction (HFpEF) along with colchicine and naproxen for pericardial inflammation, gradual cardiac recovery was achieved, but the tumour rapidly progressed within 13 days (from 22 to 35 mm). Entrectinib was reintroduced at a reduced dose (200 mg daily), yet recurrent cardiopulmonary failure occurred two weeks later, requiring permanent discontinuation. Conclusions: This case highlights that entrectinib-associated perimyocarditis can mimic infection, emphasizing the role of advanced non-invasive cardiac imaging, particularly CMR, in establishing the diagnosis. It underscores the profound therapeutic challenge of balancing the life-prolonging benefits of targeted oncological therapy against severe, recurrent cardiotoxicity.
- Open Access
- 5 December 2022
- Published by HARD Publishing Company in Polish Journal of Environmental Studies
- Vol. 32 (1) , 479-483
The Prevalence of Mycobacterium tuberculosis Complex Species in TB Patients Living in Urban Setting in Central Poland
The Mycobacterium tuberculosis complex (MTBC) consists of species and subspecies that cause tuberculosis (TB) in humans and animals. As all MTBC strains are closely related at the molecular level, the exact distinction between them is not implemented in routine diagnostic techniques but could be used for tracking the zoonotic infection route, identification of drug resistance and epidemiological profiling. This study aimed to analyse the distribution of MTBC species in TB patients in the urban setting of Warsaw (central Poland). A total of 58 clinical isolates derived from patients diagnosed with TB were analysed. All specimens were processed for culture, DNA extraction and PCR. The distribution of species was investigated using GenoType MTBC molecular assay. All TB cases analysed were caused by Mycobacterium tuberculosis. M. tuberculosis appears to be the predominant cause of TB in Warsaw, central Poland, as no cases found of human TB caused by M. bovis or other MTBC strains were found.
- 5 December 2022
- Published by HARD Publishing Company in Polish Journal of Environmental Studies
- Vol. 32 (1) , 479-483
Open AccessThe Prevalence of Mycobacterium tuberculosis Complex Species in TB Patients Living in Urban Setting in Central Poland
The Mycobacterium tuberculosis complex (MTBC) consists of species and subspecies that cause tuberculosis (TB) in humans and animals. As all MTBC strains are closely related at the molecular level, the exact distinction between them is not implemented in routine diagnostic techniques but could be used for tracking the zoonotic infection route, identification of drug resistance and epidemiological profiling. This study aimed to analyse the distribution of MTBC species in TB patients in the urban setting of Warsaw (central Poland). A total of 58 clinical isolates derived from patients diagnosed with TB were analysed. All specimens were processed for culture, DNA extraction and PCR. The distribution of species was investigated using GenoType MTBC molecular assay. All TB cases analysed were caused by Mycobacterium tuberculosis. M. tuberculosis appears to be the predominant cause of TB in Warsaw, central Poland, as no cases found of human TB caused by M. bovis or other MTBC strains were found.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
ß-Escin and chokeberry extract diet supplementation in healthy smokers as potential anti- inflammatory and antioxidant protection – a pilot study
Introduction: β-Escin is a mixture of triterpenoid saponins extracted from the fruit of horse chestnut tree (Aesculus hippocastanum. L). Recent advances in the understanding of β-escin potent anti-inflammatory effects provides rationale for its novel uses beyond the current vascular indications. The active compounds found in chokeberry (Aronia melanocarpa) also exhibit antioxidant activity. The aim of the study was to evaluate the antioxidant and anti-inflammatory effects of β-escin and chokeberry extract used as functional food in healthy tobacco smokers. Methods: We recruited 9 smoking participants who received 10 mg of water soluble β-escin and 5 mg of chokeberry juice concentrate for 2 weeks. Control group included 5 healthy nonsmokers with no escin and chokeberry supplementation. The spirometry and sputum induction were performed in study patients at baseline (V0), after 1 (V1) and 2 weeks (V2) of escin and chokeberry supplementation. In controls, the same procedures were conducted at V0 and V1 time points. The antioxidant capacity, acetaldehyde, IL-6 and IL-8 level were measured in sputum. Results: An elevated baseline IL-6 level (p=0.03) but not IL-8 (p=0.81) or acetaldehyde (p=0.07) levels were found in smokers compared to non-smokers. The decrease in the number of sputum neutrophils was observed after one week of β-escin and chokeberry supplementation (p=0.04). Conclusion: This preliminary study suggested that low dose β-escin and chokeberry supplementation may be associated with significant reduction of airway neutrophil number but no other evaluated biomarkers, further studies are needed.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
ß-Escin and chokeberry extract diet supplementation in healthy smokers as potential anti- inflammatory and antioxidant protection – a pilot study
Introduction: β-Escin is a mixture of triterpenoid saponins extracted from the fruit of horse chestnut tree (Aesculus hippocastanum. L). Recent advances in the understanding of β-escin potent anti-inflammatory effects provides rationale for its novel uses beyond the current vascular indications. The active compounds found in chokeberry (Aronia melanocarpa) also exhibit antioxidant activity. The aim of the study was to evaluate the antioxidant and anti-inflammatory effects of β-escin and chokeberry extract used as functional food in healthy tobacco smokers. Methods: We recruited 9 smoking participants who received 10 mg of water soluble β-escin and 5 mg of chokeberry juice concentrate for 2 weeks. Control group included 5 healthy nonsmokers with no escin and chokeberry supplementation. The spirometry and sputum induction were performed in study patients at baseline (V0), after 1 (V1) and 2 weeks (V2) of escin and chokeberry supplementation. In controls, the same procedures were conducted at V0 and V1 time points. The antioxidant capacity, acetaldehyde, IL-6 and IL-8 level were measured in sputum. Results: An elevated baseline IL-6 level (p=0.03) but not IL-8 (p=0.81) or acetaldehyde (p=0.07) levels were found in smokers compared to non-smokers. The decrease in the number of sputum neutrophils was observed after one week of β-escin and chokeberry supplementation (p=0.04). Conclusion: This preliminary study suggested that low dose β-escin and chokeberry supplementation may be associated with significant reduction of airway neutrophil number but no other evaluated biomarkers, further studies are needed.